Land: Canada
Sprog: engelsk
Kilde: Health Canada
IBANDRONIC ACID (IBANDRONATE SODIUM)
HOFFMANN-LA ROCHE LIMITED
M05BA06
IBANDRONIC ACID
1MG
LIQUID
IBANDRONIC ACID (IBANDRONATE SODIUM) 1MG
INTRAVENOUS
2ML
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0132573001; AHFS:
CANCELLED POST MARKET
2006-05-17
IBANDRONATE (BM 21.0955) - 1 - PRODUCT MONOGRAPH Pr BONDRONAT ® (ibandronate sodium injection) 1 mg/mL of ibandronic acid, 1mL, 2mL Ampoules Bone Metabolism Regulator (Bisphosphonate) Hoffmann-La Roche Ltd./Ltee DATE OF PREPARATION: 2455 Meadowpine Boulevard June 3, 1998 Mississauga, Ontario L5N 6L7 DATE OF REVISION: February 13, 2004 Control Number: 088161,088162,088163 ™ Trade Mark of F. Hoffmann-La Roche AG used under license © Copyright 1998 - Hoffmann-La Roche Limited IBANDRONATE (BM 21.0955) - 2 - NAME OF DRUG PR BONDRONAT ® (IBANDRONATE SODIUM INJECTION) 1 MG/ML OF IBANDRONIC ACID, 1ML, 2ML AMPOULES THERAPEUTIC CLASSIFICATION BONE METABOLISM REGULATOR (BISPHOSPHONATE) ACTIONS AND CLINICAL PHARMACOLOGY Bondronat ® (ibandronate) belongs to the class of bisphosphonates which act primarily on bone. This tissue specificity is based upon the high affinity of bisphosphonates for bone mineral. The major effect of ibandronate is to inhibit osteoclast-mediated bone resorption without any inhibitory effect on mineralization, although the precise mechanism is not clear. In patients with bone metastases, the inhibitory effect of ibandronate on tumor induced osteolysis, and specifically on tumor-induced hypercalcemia, is characterized by a decrease in serum calcium and urinary calcium excretion. Normalization of serum calcium levels was achieved in 75 percent of patients with doses ranging from 2 to 4 mg ibandronate administered as an intravenous infusion over 2 hours. Several variables interfere with a precise assessment of the duration of the effect. Variations in the tumor load, in the amount and type of osteolytic mediators produced by the tumor cells, concomitant anticancer therapy and the renal handling of calcium can influence the duration of action _._ Prior to initiation of therapy with ibandronate, the state of negative fluid balance requires vigorous and adequate hydration with isotonic saline (0.9% w/v). Normalization of blood calcium levels by ibandronate in adequately hydrated patients may also norma Læs hele dokumentet